M

otivated by a stock price that tripled over the past 10 days and in real need for new cash, MannKind (MNKD) sold 10 million shares in an overnight stock offering priced at $6 per share. After fees, the sale nets the struggling peddler of Afrezza, an inhaled insulin, just under $58 million.

MannKind remains a failing business with a bloated $700 million market valuation, so think of the new financing as a small bandage on a gaping wound. The company burned through $23 million in cash during the third quarter while managing to sell (on a net basis) just $1.8 million to $2.2 million of Afrezza, according to preliminary financial results disclosed Wednesday.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Biotech newsletter — The Readout

Your daily guide to what’s new in biotech.